Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Diabetes, Drug Treatment, and Mortality in COVID-19: A Multinational Retrospective Cohort Study
Jennifer E. Nyland, Nazia Raja‐Khan, Kerstin Bettermann, et al.
Diabetes (2021) Vol. 70, Iss. 12, pp. 2903-2916
Open Access | Times Cited: 63

Showing 1-25 of 63 citing articles:

A global federated real-world data and analytics platform for research
Matvey B. Palchuk, Jack London, David Pérez-Rey, et al.
JAMIA Open (2023) Vol. 6, Iss. 2
Open Access | Times Cited: 169
Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis
Nam Nhat Nguyen, Dung Si Ho, Hung Song Nguyen, et al.
Metabolism (2022) Vol. 131, pp. 155196-155196
Open Access | Times Cited: 66
Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression
Timotius Ivan Hariyanto, Denny Intan, Joshua Edward Hananto, et al.
Diabetes Research and Clinical Practice (2021) Vol. 179, pp. 109031-109031
Open Access | Times Cited: 52
The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis
Yidan Chen, Xingfei Lv, Sang Lin, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 33
Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
Alba Sebastián-Martín, Belén G. Sánchez, José María Mora-Rodríguez, et al.
Biomedicines (2022) Vol. 10, Iss. 8, pp. 2026-2026
Open Access | Times Cited: 31
Obesity and COVID-19: Mechanistic Insights From Adipose Tissue
Lili Yu, Xiaoying Zhang, Sarah Ye, et al.
The Journal of Clinical Endocrinology & Metabolism (2022) Vol. 107, Iss. 7, pp. 1799-1811
Open Access | Times Cited: 27
DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes
Snehasish Nag, Samanwita Mandal, Oindrila Mukherjee, et al.
Future Virology (2023) Vol. 18, Iss. 5, pp. 321-333
Open Access | Times Cited: 20
Antidiabetic agent use and clinical outcomes in patients with diabetes hospitalized for COVID-19: a systematic review and meta-analysis
Jordan N. Keels, Isabella R. McDonald, Christopher S. Lee, et al.
Frontiers in Endocrinology (2025) Vol. 15
Open Access
Noninsulin‐based antihyperglycemic medications in patients with diabetes and COVID‐19: A systematic review and meta‐analysis
Mahmoud Nassar, Hazem Abosheaishaa, Awadhesh Kumar Singh, et al.
Journal of Diabetes (2023) Vol. 15, Iss. 2, pp. 86-96
Open Access | Times Cited: 13
Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis
Sabrina Schlesinger, Alexander Lang, Nikoletta Christodoulou, et al.
Diabetologia (2023) Vol. 66, Iss. 8, pp. 1395-1412
Open Access | Times Cited: 12
Association of Glucose-Lowering Drugs With Outcomes in Patients With Diabetes Before Hospitalization for COVID-19
Zheng Zhu, Qingya Zeng, Qinyu Liu, et al.
JAMA Network Open (2022) Vol. 5, Iss. 12, pp. e2244652-e2244652
Open Access | Times Cited: 21
Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression
Hikmat Permana, Theo Audi Yanto, Timotius Ivan Hariyanto
Diabetes Research and Clinical Practice (2022) Vol. 195, pp. 110205-110205
Open Access | Times Cited: 20
The Effect of Antihyperglycemic Medications on COVID-19: A Meta-analysis and Systematic Review from Observational Studies
Zhi-Hui Song, Qiao-Ming Huang, Shan-Shan Xu, et al.
Therapeutic Innovation & Regulatory Science (2024) Vol. 58, Iss. 4, pp. 773-787
Closed Access | Times Cited: 3
The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease
Jerry R. Colca, Philipp E. Scherer
Molecular Metabolism (2021) Vol. 55, pp. 101409-101409
Open Access | Times Cited: 25
The Potential Roles of Post-Translational Modifications of PPARγ in Treating Diabetes
Xiaohui Ji, Wenqian Zhang, Liqin Yin, et al.
Biomolecules (2022) Vol. 12, Iss. 12, pp. 1832-1832
Open Access | Times Cited: 17
Decreased Circulating Dipeptidyl Peptidase-4 Enzyme Activity Is Prognostic for Severe Outcomes in Covid-19 Inpatients
Ákos Nádasdi, György Sinkovits, Ilona Bobek, et al.
Biomarkers in Medicine (2022) Vol. 16, Iss. 5, pp. 317-330
Open Access | Times Cited: 16
GRP78, a Novel Host Factor for SARS-CoV-2: The Emerging Roles in COVID-19 Related to Metabolic Risk Factors
Jihoon Shin, Shinichiro Toyoda, Atsunori Fukuhara, et al.
Biomedicines (2022) Vol. 10, Iss. 8, pp. 1995-1995
Open Access | Times Cited: 16
Geospatial Modeling of Health, Socioeconomic, Demographic, and Environmental Factors with COVID-19 Incidence Rate in Arkansas, US
Yaqian He, Paul J. Seminara, Xiao Huang, et al.
ISPRS International Journal of Geo-Information (2023) Vol. 12, Iss. 2, pp. 45-45
Open Access | Times Cited: 9
Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes
Andreana Foresta, Luisa Ojeda‐Fernández, Giulia Macaluso, et al.
Clinical Therapeutics (2023) Vol. 45, Iss. 4, pp. e115-e126
Open Access | Times Cited: 9
Insight on Infections in Diabetic Setting
Bianca Pari, Matteo Gallucci, Alberto Ghigo, et al.
Biomedicines (2023) Vol. 11, Iss. 3, pp. 971-971
Open Access | Times Cited: 9
The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism
Yajnavalka Banerjee, Anca Pantea Stoian, José Silva‐Nunes, et al.
Expert Opinion on Drug Safety (2021) Vol. 20, Iss. 11, pp. 1309-1315
Open Access | Times Cited: 22
Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 — A systematic review and meta-analysis
Ahmad Fariz Malvi Zamzam Zein, Wilson Matthew Raffaello
Primary care diabetes (2021) Vol. 16, Iss. 1, pp. 162-167
Open Access | Times Cited: 21
COVID-19 and diabetes—Two giants colliding: From pathophysiology to management
Maria Chiara Pelle, Isabella Zaffina, Michele Provenzano, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 13
Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registry analysis
Giulia Ferrannini, Lars H. Lund, Lina Benson, et al.
European Heart Journal - Cardiovascular Pharmacotherapy (2022) Vol. 9, Iss. 1, pp. 10-17
Open Access | Times Cited: 12
Non-Insulin Novel Antidiabetic Drugs Mechanisms in the Pathogenesis of COVID-19
Teodor Salmen, Valeria-Anca Pietroșel, Bianca-Margareta Mihai, et al.
Biomedicines (2022) Vol. 10, Iss. 10, pp. 2624-2624
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top